Sarasota, Florida -- Omeza, LLC successfully maxed out its current funding round limit at $7MM in July, having already raised $5.75MM as of its April 1 target. The additional funds closed just prior to the company’s second board meeting held last week at the company’s headquarters.
According to company founder and CEO Tom Gardner, the level of interest actually exceeded the agreed-upon investment limits of this round as set by the Board. Total investment in Omeza through the first two rounds is now $8MM.
Omeza (omeza.com) is a medtech and consumer healthcare products company focused on skin, the largest organ in the human body and part of the integumentary vital organ system. Omeza’s mission is to heal chronic wounds and prevent their recurrence. Omeza products are available for purchase by consumers on Amazon, and at selected independently owned pharmacies. Inquiries from medical and health professionals should be directed to firstname.lastname@example.org.
Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.